Slotnik Capital LLC Acquires Shares of 300,000 Silk Road Medical, Inc (NASDAQ:SILK)

Slotnik Capital LLC bought a new position in Silk Road Medical, Inc (NASDAQ:SILK) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 300,000 shares of the company’s stock, valued at approximately $8,112,000. Silk Road Medical comprises 4.0% of Slotnik Capital LLC’s portfolio, making the stock its 10th biggest position. Slotnik Capital LLC owned 0.74% of Silk Road Medical at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Magnetar Financial LLC bought a new position in Silk Road Medical in the 2nd quarter valued at $53,279,000. Armistice Capital LLC bought a new position in shares of Silk Road Medical in the fourth quarter worth about $21,693,000. Goldman Sachs Group Inc. increased its stake in Silk Road Medical by 707.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,010,983 shares of the company’s stock worth $24,675,000 after buying an additional 1,762,048 shares during the period. Rubric Capital Management LP bought a new stake in Silk Road Medical during the 4th quarter valued at about $17,520,000. Finally, Kennedy Capital Management LLC purchased a new stake in Silk Road Medical in the 1st quarter valued at about $18,981,000.

Silk Road Medical Stock Down 0.0 %

Silk Road Medical stock opened at $27.49 on Tuesday. The company has a quick ratio of 6.69, a current ratio of 7.63 and a debt-to-equity ratio of 0.49. The firm has a market cap of $1.12 billion, a P/E ratio of -20.07 and a beta of 1.53. The business has a fifty day moving average of $27.15 and a two-hundred day moving average of $23.20. Silk Road Medical, Inc has a twelve month low of $6.08 and a twelve month high of $27.51.

Silk Road Medical (NASDAQ:SILK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Silk Road Medical had a negative return on equity of 37.30% and a negative net margin of 29.53%. The company had revenue of $51.20 million for the quarter, compared to analysts’ expectations of $49.74 million. During the same quarter last year, the company earned ($0.35) earnings per share. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. On average, analysts forecast that Silk Road Medical, Inc will post -1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SILK has been the topic of a number of research reports. Argus lowered shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research report on Thursday, July 11th. Stifel Nicolaus restated a “hold” rating and set a $27.50 price objective (up from $23.00) on shares of Silk Road Medical in a report on Wednesday, July 17th. Finally, Lake Street Capital reiterated a “hold” rating and issued a $27.50 target price (down from $28.00) on shares of Silk Road Medical in a report on Tuesday, June 18th. Two research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $20.29.

Insider Buying and Selling at Silk Road Medical

In other news, EVP Kevin M. Klemz sold 2,268 shares of Silk Road Medical stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $27.10, for a total value of $61,462.80. Following the transaction, the executive vice president now owns 162,926 shares of the company’s stock, valued at approximately $4,415,294.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.90% of the company’s stock.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.